Chemistry:Mitoquinone mesylate
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | MitoQ |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C38H47O7PS |
| Molar mass | 678.82 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mitoquinone mesylate (MitoQ) is a synthetic analogue of coenzyme Q10 which has antioxidant effects. It was first developed in New Zealand in the late 1990s.[1] It has significantly improved bioavailability and improved mitochondrial penetration compared to coenzyme Q10,[2][3] and has shown potential in a number of medical indications,[4][5][6][7] being widely sold as a dietary supplement.[8][9]
A 2014 review found insufficient evidence for the use of mitoquinone mesylate in Parkinson's disease and other movement disorders.[10]
See also
References
- ↑ Taylor K, Smith R, "Mitoquinone derivatives used as mitochondrially targeted antioxidants.", US patent abandoned 20060229278, published 12 October 2006, assigned to Antipodean Pharmaceuticals Inc
- ↑ "Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives". Acta Pharmaceutica Sinica B 8 (6): 862–880. October 2018. doi:10.1016/j.apsb.2018.05.006. PMID 30505656.
- ↑ "Coenzyme Q10 Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic Diseases". International Journal of Molecular Sciences 21 (21): 7870. October 2020. doi:10.3390/ijms21217870. PMID 33114148.
- ↑ "Targeting Mitochondria in Cardiovascular Diseases". Current Pharmaceutical Design 22 (37): 5698–5717. 2016. doi:10.2174/1381612822666160822150243. PMID 27549376.
- ↑ "Mitochondria-Targeted Antioxidants: Future Perspectives in Kidney Ischemia Reperfusion Injury". Oxidative Medicine and Cellular Longevity 2016: 2950503. 2016. doi:10.1155/2016/2950503. PMID 27313826.
- ↑ "Small molecules as therapeutic drugs for Alzheimer's disease". Molecular and Cellular Neurosciences 96: 47–62. April 2019. doi:10.1016/j.mcn.2019.03.001. PMID 30877034.
- ↑ "Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone". Antioxidants 9 (10): 943. October 2020. doi:10.3390/antiox9100943. PMID 33019512.
- ↑ "The Effect of MitoQ on Aging-Related Biomarkers: A Systematic Review and Meta-Analysis". Oxidative Medicine and Cellular Longevity 2018: 8575263. 2018. doi:10.1155/2018/8575263. PMID 30116495.
- ↑ "Targeting reactive oxygen species (ROS) to combat the age-related loss of muscle mass and function". Biogerontology 21 (4): 475–484. August 2020. doi:10.1007/s10522-020-09883-x. PMID 32447556.
- ↑ "Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone". CNS Drugs 28 (1): 63–8. January 2014. doi:10.1007/s40263-013-0124-4. PMID 24242074.
 |  |
